Poolbeg Pharma receives South Korea patent for POLB 001
South Korea has granted a patent to Poolbeg Pharma plc for POLB 001, a treatment for cancer immunotherapy-associated cytokine release syndrome (CRS). The patent, titled "Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome," covers POLB 001 and the use of p38 MAP kinase inhibitors to prevent CRS in South Korea.
According to a press release, the patent expires in 2044. POLB 001 is an inhibitor of the p38 MAP kinase, which is being developed as a preventative treatment for CRS, a complication associated with cancer immunotherapies. This latest patent grant for South Korea strengthens Poolbeg Pharma's intellectual property portfolio for POLB 001, which already includes patents in Europe, Canada, and Australia, as well as pending applications in other territories.
The company's CEO, Jeremy Skillington, stated that this addition to their international patent estate enhances POLB 001's appeal to potential partners and reflects the ongoing progress in their cancer immunotherapy programme.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
